- Home
- BWLP vs MNKD Comparison
BWLP vs MNKD Comparison
Compare BWLP & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BWLP | MNKD |
|---|---|---|
| Founded | 1935 | 1991 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | BWLP | MNKD |
|---|---|---|
| Price | $12.92 | $5.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.08 |
| AVG Volume (30 Days) | 425.6K | ★ 3.4M |
| Earning Date | 12-02-2025 | 11-05-2025 |
| Dividend Yield | ★ 10.19% | N/A |
| EPS Growth | N/A | ★ 23.47 |
| EPS | ★ 1.14 | 0.10 |
| Revenue | ★ $3,693,482,000.00 | $313,787,000.00 |
| Revenue This Year | N/A | $21.54 |
| Revenue Next Year | $8.16 | $22.21 |
| P/E Ratio | ★ $11.57 | $58.94 |
| Revenue Growth | 2.54 | ★ 17.43 |
| 52 Week Low | $7.86 | $3.38 |
| 52 Week High | $16.60 | $6.75 |
Technical Indicators
Market Signals| Indicator | BWLP | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 58.70 | 46.17 |
| Support Level | $12.31 | $5.59 |
| Resistance Level | $12.65 | $6.12 |
| Average True Range (ATR) | 0.22 | 0.18 |
| MACD | 0.10 | -0.04 |
| Stochastic Oscillator | 83.57 | 12.82 |
Price Performance
Historical ComparisonAbout BWLP BW LPG Limited
BW LPG Ltd is an LPG shipping. It uses pioneering technology to power its vessels with cleaner-burning liquefied petroleum gas (LPG) and invest in R&D to take towards a zero-carbon future. The company is organized into two main segments: The shipping segment and the product services segment which buy and sell liquid petroleum gas and deliver it to customers. It generates the majority of its revenue from the shipping segment.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.